NeuBase Presents New Preclinical Data at ASGCT 2022 for Its DM1 Program Demonstrating Wide Tissue Distribution and Supporting a Differentiated Whole-Body Treatment Solution
Stock Information for NeuBase Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.